Next Science Limited announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the sale of XPerience No Rinse Antimicrobial Solution as a medical device in the United States. Sales of XPerience in the US will commence immediately. XPerience enters the market as a single step application where the residual solution remains in the surgical site after closure and continues to help defend against pathogens for several hours, giving surgeons a simple and effective adjunct to help prevent surgical site and post-operative infections. XPerience is designed for use in virtually every open surgery case, with our initial focus being on: Shoulder, Hip, Knee, Trauma and Podiatry. SSI is the second largest cause of hospital acquired infection in the US and a major cause of surgical complications and increased morbidity and mortality across the world. The use of XPerience No Rinse Antimicrobial Solution can help prevent costly hospital re-admissions. In the US alone, it is estimated that surgical site infections contribute an additional USD 3.5 billion to USD 10 billion to the cost of healthcare. Next Science's initial sales focus will be the US orthopaedic surgery market of 5.3 million surgeries per year in 2010; a market opportunity of over $1 billion per annum. The potential global market for XPerience is greater than USD 15 billion per annum. Key clinical studies to provide additional evidence for Next Science to drive widespread adoption in the surgical community are commencing. XPerience will be sold in the US using a third-party distribution network of over 300 commission agents managed by Next Science. Next Science's sales network provides coverage to service more than 90% of the US including the 15,000 Hospitals and Ambulatory Surgery Centres that carry out more than 100 million surgical procedures in the US annually.